BIIB Stock Biogen Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / BIIB Stock

Biogen Inc (BIIB) price per share as of 13 Jul 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 211.01M
Avg Daily Volume 1.75M
Market Cap 55.32B
Volatility 32.41% MEDIUM

BIOGEN INC (BIIB) OVERVIEW

BIIB stock is a pharmaceutical products company traded on Nasdaq. It is valued at 55.32B US dollars. There are 211.01M shares outstanding which Biogen Inc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 32.41% stock on average. It brought investors a total return of 24.10% over the last 12 months. Biogen Inc stock is relatively cheap. It's P/E ratio is below the market average.

Biogen Inc (BIIB) STOCK PRICE PERFORMANCE

BIIB SHAREHOLDER'S RETURN

Earnings Per Share 14.04
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High

BIIB LATEST NEWS

Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?

One of Biogen's drugs could put us on a path to delaying disease progression.

The Sad Truth: This Biotech Investing Strategy Almost Always Works

We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.

Biogen And Alzheimer's Disease: Reasons For Caution

Biogen has changed numbers of participants in its aducanumab clinical trial and statistical methods in its BAN2401 clinical trial - both of which are cause for concern. Some ApoE4 carriers either drop

Do Surprising Alzheimer's Disease Results Make Biogen Stock a Smart Buy Now?

The clinical trail results are a big deal, but they don't necessarily make the pharmaceutical company's shares a good deal.

Why CTI BioPharma Corp. Is Sinking Today

Shares tumble in response to disappointing clinical news. Here's what investors need to know.

Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen

Biogen rallied strongly after final analysis of phase 2 Alzheimer’s candidate.AC Immune, whose drug has similarities with Biogen’s, also went up.Some, like Leerink’s Porges, thinks the hype is prematu

Biogen Inc (BIIB) TECHNICAL INDICATORS

Name Value Action
RSI(14) 73.03 Overbought
CMO(14) 46.06 Strong buy
ADX(14) 33.87 Buy
Williams %R -23.51 Overbought

BIIB STOCK VALUATION

BIIB Industry Sector Market
Price to Earnings 18.67 31.69 27.49 42.97
Price to Book Value 3.94 6.79 6.25 7.18
Price to Sales 4.39 3.59 3.41 4.95
Return on Equity 23.20% 11.07% 10.16% 19.24%
Return on Assets 12.50% 5.57% 4.77% 8.57%
All values TTM (trailing twelve months). Source: Quandl.com

BIIB FORUM DISCUSSIONS